

*RECORDED
OCT 21 1997
SEARCHED*

* * * * *

FILE 'USPAT' ENTERED AT 15:16:53 ON 24 OCT 1997

* * * * *

* W E L C O M E T O T H E *

* U. S. P A T E N T T E X T F I L E *

* * * * *

=> e noelle/in

E#	FILE	FREQUENCY	TERM
--	---	-----	-----
E1	USPAT	1	NOELL, ROBERT E JR/IN
E2	USPAT	1	NOELL, ROCKY/IN
E3	USPAT	0 -->	NOELLE/IN
E4	USPAT	1	NOELLE, CALVIN D/IN
E5	USPAT	1	NOELLE, JOHN A/IN
E6	USPAT	1	NOELLE, THOMAS J/IN
E7	USPAT	3	NOELLER, HANS G/IN
E8	USPAT	1	NOELLERT, LARRY L/IN
E9	USPAT	1	NOELPP, BERNHARD/IN
E10	USPAT	2	NOELSCHER, CHRISTOPH/IN
E11	USPAT	1	NOELTE, ECKHARD/IN
E12	USPAT	1	NOELTING, C BERNARD/IN

=> s (24(w)31 or 89(w)76) and (gp39 or cd40(w)ligand or cd40l or 5c8)

1378724 24
766111 31
1096 24(W)31
145433 89
430712 76
162 89(W)76
6 GP39
66 CD40
16421 LIGAND
29 CD40(W)LIGAND
7 CD40L
32 5C8
L1 9 (24(W)31 OR 89(W)76) AND (GP39 OR CD40(W)LIGAND OR CD40L OR
5C
8)

=> d 11 1-9

1. 5,652,243, Jul. 29, 1997, Methods of using enantiomerically pure hydroxylated xanthine compounds; James A. Bianco, et al., 514/263, 262, 265, 814 :IMAGE AVAILABLE:
2. 5,648,357, Jul. 15, 1997, Enatiomerically pure hydroxylated xanthine compounds; James A. Bianco, et al., 514/263, 267, 270, 271 :IMAGE AVAILABLE:
3. 5,629,315, May 13, 1997, Treatment of diseases using enantiomerically pure hydroxylated xanthine compounds; James A. Bianco, et al., 514/263, 866 :IMAGE AVAILABLE:
4. 5,621,102, Apr. 15, 1997, Process for preparing enantiomerically pure xanthine derivatives; James A. Bianco, et al., 544/267 :IMAGE AVAILABLE:
5. 5,620,984, Apr. 15, 1997, Enatiomerically pure hydroxylated xanthine

compounds to treat inflammatory diseases; James A. Bianco, et al.,
514/263 :IMAGE AVAILABLE:

6. 5,612,349, Mar. 18, 1997, Enantiomerically pure hydroxylated xanthine
compounds to treat shock symptoms; James A. Bianco, et al., 514/263, 921
:IMAGE AVAILABLE:

7. 5,580,874, Dec. 3, 1996, Enatiomerically pure hydroxylated xanthine
compounds; James A. Bianco, et al., 514/263 :IMAGE AVAILABLE:

8. 5,580,873, Dec. 3, 1996, Enatiomerically pure hydroxylated xanthine
compounds to treat proliferative vascular diseases; James A. Bianco, et
al., 514/263 :IMAGE AVAILABLE:

9. 5,567,704, Oct. 22, 1996, R-enatiomerically pure hydroxylated
xanthine compounds to treat baldness; James A. Bianco, et al., 514/263,
262 :IMAGE AVAILABLE:

=> s l1 and (24(w)31 or 89(w)76) (p)antibod?

1378724 24

766111 31

145433 89

430712 76

25216 ANTIBOD?

7 (24(W)31 OR 89(W)76) (P)ANTIBOD?

L2 0 L1 AND (24(W)31 OR 89(W)76) (P)ANTIBOD?

et on as ''
? begin 55,72,154,399,351

24oct97 14:24:18 User208760 Session D905.2
\$0.00 0.004 Hrs File410
\$0.00 Estimated cost File410
\$0.00 Estimated cost this search
\$0.03 Estimated total session cost 0.005 Hrs.

SYSTEM:OS - DIALOG OneSearch
File 55:BIOSIS PREVIEWS(R) 1985-1997/Oct W3
(c) 1997 BIOSIS
File 72:EMBASE 1985-1997/Oct W1
(c) 1997 Elsevier Science B.V.
*File 72: EMTAGS no longer in EMBASE as of 1/98. Type: HELP NEWS 72
for details.
File 154:MEDLINE(R) 1985-1997/Dec W3
(c) format only 1997 Knight-Ridder Info
File 399:CA SEARCH(R) 1967-1997/UD=12716
(c) 1997 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement.
For format prices, including formats 6 & 8, see HELP RATES 399.
File 351:DERWENT WPI 1963-1997/UD=9742;UP=9739;UM=9737
(c) 1997 Derwent Info Ltd
*File 351: See HELP NEWS FAQ 351 for reload information.
*File 351: See HELP NEWS 351 for updated faster-See HELP NEWS 351
British applications now updated faster-See HELP NEWS 351

Set	Items	Description
---	---	---
? s	(24(w)31 or 89(w)76)(10n)	(antibod? and (gp39 or cd40L or cd40(w)ligand or 5c8)

>>>Unmatched parentheses

? PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES
? PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES
? s (24(w)31 or 89(w)76)(10n)antibod? and (gp39 or cd40L or cd40(w)ligand or 5c8)

924083	24
386210	31
855	24(W)31
165916	89
133742	76
45	89(W)76
990447	ANTIBOD?
3	(24(W)31 OR 89(W)76)(10N)ANTIBOD?
344	GP39
1259	CD40L
4799	CD40
179456	LIGAND
1836	CD40(W)LIGAND
59	5C8
S1	2 (24(W)31 OR 89(W)76)(10N)ANTIBOD? AND (GP39 OR CD40L OR CD40(W)LIGAND OR 5C8)

? t s1/3/all

1/3/1 (Item 1 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)

127049215 CA: 127(4)49215d PATENT

Mouse monoclonal antibody 24-31, humanized antibodies to human gp39 antigen, and therapeutic uses in treatment of autoimmune diseases and other diseases

INVENTOR(AUTHOR): Black, Amelia; Hanna, Nabil; Padlan, Eduardo A.; Newman, Roland A.

LOCATION: USA

ASSIGNEE: Idec Pharmaceutical Corporation

PATENT: PCT International ; WO 9717446 A2 DATE: 19970515

APPLICATION: WO 96US17875 (19961107) *US 554840 (19951107)

PAGES: 107 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/13A; C07K-016/46B; C07K-016/28B; A61K-039/395B DESIGNATED COUNTRIES: AU; CN; FI; HU; JP; KR; NO; NZ DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE

1/3/2 (Item 1 from file: 351)

DIALOG(R) File 351:DERWENT WPI

(c)1997 Derwent Info Ltd. All rts. reserv.

011303130

WPI Acc No: 97-281035/199725

XRAM Acc No: C97-090374

Humanised **antibody** capable of competing with, or derived from, murine **24-31 antibody** - useful to modulate **gp39** expression or inhibiting **gp39/CD40** interaction

Patent Assignee: IDEC PHARM CORP (IDEC-N)

Inventor: BLACK A; HANNA N; NEWMAN R A; PADLAN E A

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
WO 9717446	A2	19970515	WO 96US17875	A	19961107		199725 B
AU 9711576	A	19970529	AU 9711576	A	19961107		199737

Priority Applications (No Type Date): US 95554840 A 19951107

Filing Details:

Patent	Kind	Filing Notes	Application	Patent
--------	------	--------------	-------------	--------

WO 9717446 A2

Designated States (National): AU CN FI HU JP KR NO NZ

Designated States (Regional): AT BE CH DE DK ES FI FR GB GR IE IT LU MC
NL PT SE

AU 9711576 A Based on WO 9717446

Language, Pages: WO 9717446 (E, 106)